title: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.
abstract: Metabolic syndrome (MS) is a newly identified risk factor in chronic liver disease (CLD) and hepatocellular carcinoma (HCC). The aim of this study was to analyze the pathological characteristics of HCC and nontumoral liver in patients with MS as the only risk factor for liver disease in comparison with those that developed in the course of other CLDs in order to provide further insight into the physiopathology of HCC associated with MS. HCC patients with features of MS as the only risk factor for liver diseases (MS group, n = 31) were compared to HCC patients with overt causes of CLD (CLD group, n = 81) or without causes of CLD (cryptogenic group, n = 16) who underwent surgical resection during the same period of time. Among the patients of the MS group, there were 30 males and 1 female. In comparison with the patients with HCC of the CLD group, the patients with MS were older (mean age: 67+/- 7 versus 59 +/- 14 years, P < 0.01), and the background liver was significantly more often free of significant fibrosis (F0-F2: 65% in the MS group versus 26% in the CLD group, P < 0.001). In addition, HCCs associated with MS were more often well differentiated (65% versus 28%, P < 0.001). Five HCCs, all from the MS group, developed on a preexisting liver cell adenoma, with three of them showing typical histological features of telangiectatic adenoma.
  
  
  CONCLUSIONS
  This study shows that HCCs in patients with features of MS as the only risk factor for liver disease have distinct morphological characteristics and mainly occur in the absence of significant fibrosis in the background liver. In addition, some of them arise through malignant transformation of a preexisting liver cell adenoma.
authors.affiliation: Service d'Anatomie Pathologique, Hôpital Beaujon, Clichy, France. vparadis@teaser.fr
authors.forename: Valérie
authors.initials: V
authors.lastname: Paradis
authors.forename: Stéphane
authors.initials: S
authors.lastname: Zalinski
authors.forename: Emna
authors.initials: E
authors.lastname: Chelbi
authors.forename: Nathalie
authors.initials: N
authors.lastname: Guedj
authors.forename: Françoise
authors.initials: F
authors.lastname: Degos
authors.forename: Valérie
authors.initials: V
authors.lastname: Vilgrain
authors.forename: Pierre
authors.initials: P
authors.lastname: Bedossa
authors.forename: Jacques
authors.initials: J
authors.lastname: Belghiti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000473:pathology* / Q000503:physiopathology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology / Q000601:surgery; D008103:Liver Cirrhosis / Q000473:pathology*; D008107:Liver Diseases / Q000473:pathology; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000473:pathology* / Q000503:physiopathology; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors